Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical pr…
$20.14+3.55%
报价 2026-11-06
市值
$7.01B
EV
$9.21B
PE (TTM)
41.2x
预期 PE (FY2026)
19.3x
52 周区间距高点 -6.4%
$11.48$21.51
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 1.10 → 1.23（1.1x） | 16.3 |
| FY+32028-12 | 1.2x | 1.10 → 1.46（1.3x） | 13.8 |
毛利率 39% · TTM 收入 $3196M · 基数 EPS 1.10（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AMRXAmneal Pharmaceuticals, Inc. | $7.01B | +3.5% | +6.2% | 42% | 41.2x | 14.1x | 78.8x | |
| LNTHLantheus Holdings, Inc. | $6.57B | -0.1% | -2.3% | 61.1% | 21.3x | 13.2x | 18.6x | |
| MIRMMirum Pharmaceuticals, Inc. | $6.09B | +0.2% | +30.9% | 81.7% | – | – | – | |
| NVSTEnvista Holdings Corp | $4.04B | +0.9% | +8.7% | 57.9% | 6.4x | 5.2x | 17.9x | Cheap |
| DYNDyne Therapeutics, Inc. | $3.37B | +4.1% | +42.9% | 0% | – | – | – | |
| TLXTelix Pharmaceuticals Limited | $3.17B | +2.2% | – | 50.8% | – | 129.6x | – | |
| BHCBausch Health Companies Inc. | $3.06B | +2.8% | +7.5% | 75% | – | 8.9x | 1.7x | |
| PRGOPerrigo Company plc | $2.2B | +0.9% | -6.0% | 30.7% | – | – | 12.9x | |
| SUPNSupernus Pharmaceuticals, Inc. | $1.52B | -2.2% | +25.9% | 85.7% | 7.1x | 3.0x | 49.1x | Cheap GARP |
| 同行中位数 | – | – | +8.7% | 59.5% | 7.1x | 8.9x | 17.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $796.2M | $722.5M | $814.3M | $784.5M | $724.5M | $695.4M | $730.5M | $702.5M |
| Gross Margin | 42% | 44.3% | 36.5% | 34.9% | 39.5% | 36.8% | 36% | 38.4% |
| Operating Margin | 18.3% | 19.8% | 14.1% | -0% | 15.4% | 14.4% | 10.4% | 12.6% |
| Net Income | $57.7M | $62.3M | $35.1M | $2.4M | $22.4M | $12.2M | $-31.1M | $-156,000 |
| Diluted EPS | 0.18 | 0.19 | 0.11 | 0.01 | 0.07 | 0.04 | -0.1 | -0 |
| Operating Cash Flow | $-19.3M | $-28.7M | $130.3M | $118.5M | $83.8M | $7.4M | $118.1M | $141.8M |